OOIR: Observatory of International Research

Papers

(The H4-Index of Journal for Immunotherapy of Cancer is 68. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
390 A global, molecular disease characterization initiative (MDCI) in oncology clinical trials	473
92 Single cell and spatial multiplex profiling of immune cell markers in FFPE tumor tissues using the novel RNAscope™ HiPlex v2 in situ hybridization assay	207
34 Selective infiltration of Antibody-Dependent Cellular Cytoxicity (ADCC) mediating immune cells in response to treatment in a human tumor histo-culture platform	184
62 Applying machine vision to empower preclinical development of cell engager and adoptive cell therapeutics in patient-derived organoid models of solid tumors	168
Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study	165
Divergent transcriptional states and kinetics of circulating tumor-infiltrating lymphocyte repertoires with highly homologous T-cell receptor sequences in a patient during immunotherapy	163
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells	161
Leveraging mRNA technology for antigen based immuno-oncology therapies	150
Frizzled-7-targeting antibody-derived bifunctional protein retargets NK cells against triple-negative breast cancer cells via MICA-NKG2D axis	141
214 SIRPα-deficient macrophages activate polyclonal tissue-resident cytotoxic CD8 T cells to eliminate irradiation-refractory non-small cell lung carcinoma	135
Transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study	133
65 Identification of frequently presented non-mutated tumor-specific immunogens for the development of both off-the-shelf and personalized vaccines without need for tumor biopsy	133
Chrono-immunotherapy as a low-hanging fruit for cancer treatment? A call for pragmatic randomized clinical trials	130
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial	127
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma	125
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8⁺ T cell immunity to reject ‘cold’ tumors	122
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma	121
Correction: Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future	117
90 Unbiased proteomic profiling leads to the discovery of a novel non-invasive blood-based protein panel with significant positive predictive value in pancreatic and colorectal cancers	115
Biomarkers for response to TIL therapy: a comprehensive review	115
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials	113
TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy	109
GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies	108
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes	107
Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review	107

Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment	104
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors	103
372 Association of tumor mutation burden (TMB) and genomic alterations (GA) with clinical outcomes in Chinese patients with advanced solid tumors treated with tislelizumab	99
67 Cancer aneuploidy is associated with a distinct tumor immune microenvironment and impacts outcomes to immune checkpoint inhibition in nonsquamous non-small cell lung cancer	96
229 CX3CR1 in exhausted CD8 T cell states	95
217 Cytotoxicity of nicotinamide enhanced natural killer cells GDA201 is based on metabolic modulation as demonstrated by artificial intelligence assisted analysis of NK cell transcriptome and metabol	94
Skin mutation burden drives adaptive immunity and response to immunotherapy	94
73 Characterization of tumor-infiltrating T-cell repertoire in human cancers	93
Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis	93
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab	92
Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab	92
Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma	91
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma	89
Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models	88
Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy	87
Neuroblastoma: an ongoing cold front for cancer immunotherapy	86
Better understanding of ICI-induced cholangitis for better management	86
Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report	85
Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1	84
CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden	84
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma	84
Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment	82
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma	82
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma	82
Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions	82
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis	80
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer	79
Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non-small cell lung cancer	78
Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody	78
Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis	78
Expanded antigen-experienced CD160⁺CD8⁺effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia	77
Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series	77
Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis	76
Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy	76
CARs are sharpening their weapons	74
Comments on roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation	72
Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro	72
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials	71
Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis	71
Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck	69
Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming	68
Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study	68
Autophagic flux restoration enhances the antitumor efficacy of tumor infiltrating lymphocytes	68